Search Results
Jan 15, 2026, 09:53 ET Turret Capital Launches Sable, a Biotech-Driven Beauty Brand Advancing Body Contouring and Aesthetic Longevity
Era of Body Aesthetics and LongevityAs consumer interest in body-sculpting procedures and wellness-led lifestyle changes (such as GLP-1 medications) continues to surge, Sable fills a critical gap in the prestige beauty market. The product line is specifically formulated to address:
More news about: Turret Capital Management
Jan 15, 2026, 09:32 ET MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia, Inc.
Jan 14, 2026, 15:29 ET Mission Foods: NEW YEAR, NEW NUTRITION PLAN!
From GLP-1 to Keto, hear the nutrition tips and recipes you need to stay on track in the New YearIRVING, Texas, Jan. 14, 2026 /PRNewswire/ -- BACKGROUND:As the
More news about: Hillenby, LLC
Jan 14, 2026, 15:06 ET Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk
pharmaceutical giants Eli Lilly and Novo Nordisk, alleging a coordinated effort to suppress competition and limit patient access to lawful compounded GLP-1 medications.
More news about: Strive Compounding Pharmacy
Jan 14, 2026, 11:30 ET Nimbus Healthcare and Snap Kitchen Launch "Nimbus Meals" to Pair GLP-1 Therapy with Medically Tailored Meals
groups.As GLP-1 usage climbs, many patients report that appetite suppression and rapid routine changes can make it difficult to consistently hit nutrition targets. Nimbus Meals addresses this gap by delivering ready-to-heat meals built for GLP-1 journeys, focusing on protein,
More news about: Nimbus Healthcare
Jan 14, 2026, 11:01 ET RHC's 2026 Hospitality Forecast Highlights the New Rules of Influence
outpace alcohol, with intensified marketing and consumer focus on wellbeing. Fiber is expected to emerge as a key nutrient in response to GLP-1 medications, following protein's dominance in 2025. Nervous system regulation, biohacking, biomarker tracking, and AI-powered personalization
More news about: Rachel Harrison Communications
Jan 14, 2026, 10:00 ET New report reveals 2026 benefits trends: More HDHPs, preventive care, and AI-powered savings
experiences.The largest benefit trend on the horizon: Multi-agent artificial intelligenceIn a year defined by premium hikes, GLP-1 demand, and price transparency mandates, Healthee's data suggests a broader trend: employers are increasingly turning to multi-agent AI and agent-to-agent
More news about: Healthee Inc
Jan 14, 2026, 09:02 ET DripDrop® Hydration Launches Breakthrough Zero Sugar Plus - The Complete Zero Sugar Hydration
brand has developed an entirely new formula in Zero Sugar Plus, designed for daily functional use cases including fitness, recovery, travel, GLP-1 support and beyond."DripDrop Zero Sugar Plus represents the next evolution in hydration science," said John Shea, Chief Marketing
More news about: DripDrop
Jan 13, 2026, 23:00 ET 趙明琪獲任普洛斯中國首席執行官
新加坡2026年1月14日 /美通社/ -- 普洛斯集團（GLP Pte Ltd，簡稱「GLP」，即「普洛斯」，涵括其子公司統稱「集團」）宣布委任趙明琪為普洛斯中國首席執行官。該任命體現了普洛斯的長期人才發展和繼任規劃，並彰顯了其在中國加強新經濟業務平台整合、提升協同效應的重要戰略。
More news about: GLP
Jan 13, 2026, 09:00 ET Has U.S. Calorie Consumption Peaked?
Declining Birth Rates, Slower Population Growth and Rising GLP-1 Adoption Suggest Flat Food and Beverage Consumption Through 2035, According to L.E.K. Consulting AnalysisBOSTON, Jan. 13, 2026
More news about: L.E.K. Consulting
Jan 13, 2026, 08:38 ET NOW® Survey Uncovers The Wellness And Health Priorities Shaping Consumers' Supplement Use In 2026
NOW® Prebiotic Fiber with Fibersol®-2 may support normal levels of the appetite-regulating hormone GLP-1 in healthy individuals, while
More news about: NOW®
Jan 13, 2026, 08:30 ET Aon's Latest GLP-1 Research Reveals Long-Term Employer Cost Savings and Significant Reductions in Cancer Risk for Women
commercial lives, including 192,000 prescribed GLP-1 users, from July 2022 to March 2025. Aon's latest analysis reveals:GLP-1 Adherence Delivers Measurable Cost Savings: For those using GLP-1s to manage diabetes, medical cost growth was six percentage
More news about: Aon plc
Jan 13, 2026, 08:00 ET RO ANNOUNCES RESEARCH COLLABORATION TO BETTER UNDERSTAND AND IMPROVE THE REAL-WORLD PATIENT EXPERIENCE WITH GLP-1S
conditions."As GLP-1s help to transform the obesity treatment landscape, insurance coverage for the medications has remained a key hurdle for patients and providers. While prior research has focused on policy-level data, Ro's and Amgen's will importantly evaluate real-world GLP-1 coverage among
More news about: Ro
Jan 13, 2026, 06:50 ET BD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs
technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S. This investment will bring BD Neopak™ Glass Prefillable Syringe production to
More news about: BD (Becton, Dickinson and Company)
Jan 12, 2026, 16:44 ET Purpose Brands: WHY TRANSFORMATION LOOKS DIFFERENT THAN IT USED TO
Millennials also pay for apps but are less likely to pay for mental wellness apps (exercise 30%, nutrition 25% and mental wellness 20%).GLP-1 users are emerging as a new "super-engaged" health consumer segment more than twice (2-3x) as likely to join new gyms, pay for digital fitness and
More news about: Purpose Brands
Jan 12, 2026, 09:03 ET Specialty Food Association Announces SenseMaxxing as Trend of the Year Alongside Five Other Key Trends for 2026 at Winter FancyFaire*
and limited-ingredient lists.The Appetite Reset: A revolutionary rewiring between hunger and reward is happening among consumers. As GLP-1s have crossed over from celebrity gossip to a cultural phenomenon, millions are now eating with recalibrated hunger signals, so every bite must earn
More news about: Specialty Food Association
Jan 12, 2026, 08:57 ET TOM BRADY NAMED CHIEF WELLNESS OFFICER OF EMED
population health management, including GLP-1/GIP therapies, today announced that seven-time Super Bowl champion Tom Brady has been appointed Chief Wellness Officer. The appointment reflects a shared commitment to advancing medically guided GLP-1 care grounded in science, adherence,
More news about: eMed Population Health
Jan 12, 2026, 07:00 ET Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
adults with BMI ≥30 kg/m2 but who are otherwise healthy. About GLP-1 and Dual GLP-1/GIP AgonistsActivation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve
More news about: Viking Therapeutics, Inc.
Jan 12, 2026, 05:30 ET Bukan Hanya Turunkan Berat Badan: GLP-1 RA, Obat Modern untuk Manajemen Obesitas Dikaitkan dengan Turunnya Belanja Alkohol dan Rokok
setidaknya satu pengguna obat GLP-1 RA Novo Nordisk untuk pengelolaan berat badan mengalami penurunan pengeluaran belanja dari tahun ke tahun, terutama karena berkurangnya pengeluaran untuk alkohol dan produk tembakau/rokok dibandingkan rumah tangga tanpa pengguna obat GLP-1 RA.Meskipun analisis
More news about: Novo Nordisk Indonesia
Jan 12, 2026, 05:00 ET Pipe17 Extends Its Network to Support Order Management for Agentic Commerce
unifies orders, inventory, products and fulfillments across selling channels (DTC, B2B, retail and agentic), ERPs and fulfillment locations. Backed by GLP Capital, LFX Ventures and Blumberg Capital, Pipe17 helps innovative brands like Allbirds, Wyze and MaryRuth, and leading 3PLs like FedEx, Radial and
More news about: Pipe17
Jan 09, 2026, 13:46 ET Illuminate Rx Appoints Industry Veteran Ritu Malhotra, PharmD, as President to Advance Clarity in Pharmacy Benefits
employers and members we serve."The appointment comes as employers face significant pressures from rising specialty drug costs and soaring GLP-1 therapy utilization. Illuminate Rx's lowest net cost strategy, guided by a formulary crafted by clinical pharmacists, directly addresses these challenges
More news about: Illuminate Rx
Jan 09, 2026, 09:02 ET Prescryptive and Ilant Health Expand Employer-Direct Access to Obesity Care and Transparent GLP-1 Access at Scale
outcome tracking. Employers can now offer GLP-1 and obesity therapies with structured clinical oversight, predictable economics, and measurable outcomes.Employers are increasingly seeking alternatives to traditional GLP-1 coverage models, while pharmaceutical manufacturers
More news about: Prescryptive Health
Jan 09, 2026, 08:47 ET New Partnership Between PureWay and PPSWG Aims to Transform How America Manages Pharmaceutical Waste
pharmaceutical waste management. Millions of Americans rely on self-administered injectable medications every day, including insulin, GLP-1 therapies, migraine biologics, and autoimmune biologics. The resulting waste (billions of discarded needles and syringes) poses both an environmental
More news about: PureWay Compliance
Jan 08, 2026, 14:00 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
inhibits its interaction with the IL-17 receptor. Zepbound is the only FDA-approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity management medication."While treatment guidelines for psoriatic arthritis recommend management
More news about: Eli Lilly and Company
Jan 08, 2026, 07:00 ET Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
arms: VK2735 7.5 mg; VK2735 12.5 mg; VK2735 17.5 mg; and placebo.About GLP-1 and Dual GLP-1/GIP AgonistsActivation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve
More news about: Viking Therapeutics, Inc.